Further Study DetailsComparative In Vitro Activity of Dalbavancin (DAL) and Other Gram-Positive Agents Against a Recent Collection of European Bacterial Isolates (Simenauer, et al). Session Number 010, Presentation Number: C2-134 In this comparator study, non-duplicate, non-consecutive S. aureus (SA; n = 452), coagulase-negative staphylococci (CNS; n = 49), and beta-hemolytic streptococci (BHS; n = 90) isolates were collected from nine sites across Europe during 2011. All isolates were tested by broth microdilution according to appropriate CLSI guidelines. This analysis focused on dalbavancin (DAL) activity and the activities of vancomycin (VAN), linezolid (LZD), and daptomycin (DAP).
|MIC 90 (µg/mL)|
Surveillance data showed that dalbavancin (DAL, MIC 50/90, 0.06/0.06 µg/ml) was eight and 16-fold more active than daptomycin (DAPT) and vancomycin (VANC), respectively against SA; with MSSA and MRSA having the same MIC 90 results. CoNS was slightly more DAL-S (MIC 50, ≤0.03µg/ml). The highest staphylococcal DAL MIC was only 0.25 µg/ml (table. β-haemolytic streptococci (βHS) and VGS had DAL MICs ranging from ≤0.03 to 0.25 µg/ml (MIC 90, 0.06-0.12 µg/ml) and only enterococci showed elevated DAL MIC results. VanA phenotype-resistant E. faecalis or E. faecium had DAL MIC values at ≥1 µg/ml; VanB strains were DAL-S (MIC, ≤0.25 µg/ml).All cited DAL quantitative values were totally consistent with earlier surveillance data (2006-2009), without MIC creep.
|Organism (no.)||≤ 0.03||0.06||0.12||0.25||0.5||1||≥ 2|
|*=vancomycin MIC 90|
About Durata TherapeuticsDurata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata is currently enrolling and dosing patients in two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. Forward-looking statements Statements contained in this press release contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements about the content and timing of the filing of a New Drug Application with the U.S. Food and Drug Administration. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the “Risk Factors” section of our most recent quarterly report on Form 10-Q, which is on file with the SEC and is also available on our website. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change. Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.